國立虎尾科技大學 |

BRAF targets in melanoma = biological mechanisms, resistance, and drug discovery /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	BRAF targets in melanoma/ edited by Ryan J. Sullivan.
其他題名:	biological mechanisms, resistance, and drug discovery /
其他作者:	Sullivan, Ryan J.
出版者:	New York, NY :Springer New York : : 2015.,
面頁冊數:	viii, 204 p. :ill. (some col.), digital ; : 24 cm.;
Contained By:	Springer eBooks
標題:	Melanoma - Treatment. -
電子資源:	http://dx.doi.org/10.1007/978-1-4939-2143-0
ISBN:	9781493921430 (electronic bk.)

BRAF targets in melanoma = biological mechanisms, resistance, and drug discovery /
BRAF targets in melanomabiological mechanisms, resistance, and drug discovery /[electronic resource] :edited by Ryan J. Sullivan. - New York, NY :Springer New York :2015. - viii, 204 p. :ill. (some col.), digital ;24 cm. - Cancer drug discovery and development,v.822196-9906 ;. - Cancer drug discovery and development ;v.82..

Melanoma: Historical Context -- Melanoma Pathogenesis -- Molecular Diagnostics and Tumor Mutational Analysis -- Clinical Utility of BRAF-targeted therapy in Melanoma -- The Ethics of Randomized Trials in Oncology -- Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma -- Targeting the cell cycle and p53 in combination with BRAF-directed therapy -- Combination BRAF-directed therapy and immunotherapy -- Moving Forward: Making BRAF-Targeted Therapy Better.

This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that these drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma.

ISBN: 9781493921430 (electronic bk.)

Standard No.: 10.1007/978-1-4939-2143-0doiSubjects--Topical Terms:

778173
Melanoma
--Treatment.

LC Class. No.: RC280.M37 / B73 2015

Dewey Class. No.: 616.99477

BRAF targets in melanoma = biological mechanisms, resistance, and drug discovery /
LDR:02887nam a2200325 a 4500 001 834875
003 DE-He213
005 20150626160037.0
006 m d
007 cr nn 008maaau
008 160421s2015 nyu s 0 eng d
020 $a 9781493921430 (electronic bk.)
020 $a 9781493921423 (paper)
024 7 $a 10.1007/978-1-4939-2143-0 $2 doi
035 $a 978-1-4939-2143-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.M37 $b B73 2015
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99477 $2 23
090 $a RC280.M37 $b B812 2015
245 0 0 $a BRAF targets in melanoma $h [electronic resource] : $b biological mechanisms, resistance, and drug discovery / $c edited by Ryan J. Sullivan.
260 $a New York, NY : $b Springer New York : $b Imprint: Springer, $c 2015.
300 $a viii, 204 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Cancer drug discovery and development, $x 2196-9906 ; $v v.82
505 0 $a Melanoma: Historical Context -- Melanoma Pathogenesis -- Molecular Diagnostics and Tumor Mutational Analysis -- Clinical Utility of BRAF-targeted therapy in Melanoma -- The Ethics of Randomized Trials in Oncology -- Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma -- Targeting the cell cycle and p53 in combination with BRAF-directed therapy -- Combination BRAF-directed therapy and immunotherapy -- Moving Forward: Making BRAF-Targeted Therapy Better.
520 $a This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that these drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma.
650 0 $a Melanoma $x Treatment. $3 778173
650 1 4 $a Biomedicine. $3 593880
650 2 4 $a Cancer Research. $3 668358
650 2 4 $a Molecular Medicine. $3 668353
650 2 4 $a Medical Microbiology. $3 668401
650 2 4 $a Pharmacology/Toxicology. $3 593882
700 1 $a Sullivan, Ryan J. $3 1063740
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a Cancer drug discovery and development ; $v v.82. $3 1063741
856 4 0 $u http://dx.doi.org/10.1007/978-1-4939-2143-0
950 $a Biomedical and Life Sciences (Springer-11642)